Nifty
Sensex
:
:
11987.65
40648.47
-11.45 (-0.10%)
-3.17 (-0.01%)

Pharmaceuticals & Drugs

Rating :
50/99  (View)

BSE: 524804 | NSE: AUROPHARMA

432.35
-12.45 (-2.80%)
21-Nov-2019 | 11:59AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  444.00
  •  448.70
  •  426.60
  •  444.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3731813
  •  16134.49
  •  838.00
  •  389.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 26,056.69
  • 10.13
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 31,066.27
  • 0.56%
  • 1.72

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.87%
  • 1.73%
  • 8.56%
  • FII
  • DII
  • Others
  • 0.12%
  • 12.87%
  • 24.85%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.53
  • 10.05
  • 9.48

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.99
  • 9.04
  • 2.85

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.46
  • 8.43
  • 0.94

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.91
  • 19.17
  • 16.77

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.08
  • 4.89
  • 3.50

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.15
  • 13.10
  • 11.32

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Net Sales
5,600.47
4,751.40
17.87%
5,444.60
4,250.27
28.10%
5,292.20
4,049.09
30.70%
5,269.67
4,336.11
21.53%
Expenses
4,460.25
3,765.13
18.46%
4,298.20
3,539.21
21.45%
4,234.73
3,260.98
29.86%
4,183.29
3,310.53
26.36%
EBITDA
1,140.22
986.27
15.61%
1,146.40
711.06
61.22%
1,057.47
788.11
34.18%
1,086.38
1,025.58
5.93%
EBIDTM
20.36%
20.76%
21.06%
16.73%
19.98%
19.46%
20.62%
23.65%
Other Income
20.62
26.26
-21.48%
15.78
43.73
-63.91%
32.27
43.83
-26.37%
63.85
33.05
93.19%
Interest
40.94
35.39
15.68%
49.89
29.54
68.89%
50.08
24.72
102.59%
47.65
18.86
152.65%
Depreciation
243.31
163.68
48.65%
240.86
154.53
55.87%
186.62
156.63
19.15%
163.12
138.08
18.13%
PBT
863.83
786.62
9.82%
858.73
570.72
50.46%
816.86
650.59
25.56%
914.42
901.69
1.41%
Tax
224.37
175.42
27.90%
227.76
115.54
97.13%
231.12
122.39
88.84%
204.78
306.94
-33.28%
PAT
639.46
611.20
4.62%
630.97
455.18
38.62%
585.74
528.20
10.89%
709.64
594.75
19.32%
PATM
11.42%
12.86%
11.59%
10.71%
11.07%
13.04%
13.47%
13.72%
EPS
10.92
10.44
4.60%
10.85
7.78
39.46%
9.99
9.02
10.75%
12.16
10.16
19.69%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
21,606.94
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
4,381.48
3,575.44
Net Sales Growth
24.27%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
5.61%
22.54%
 
Cost Of Goods Sold
9,429.37
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
1,963.83
1,574.54
Gross Profit
12,177.57
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
2,417.65
2,000.90
GP Margin
56.36%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
55.18%
55.96%
Total Expenditure
17,176.47
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
3,418.22
2,752.25
Power & Fuel Cost
-
556.79
470.95
437.14
419.26
359.60
349.84
324.72
232.36
208.26
194.91
% Of Sales
-
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
4.75%
5.45%
Employee Cost
-
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
425.07
324.13
% Of Sales
-
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
9.70%
9.07%
Manufacturing Exp.
-
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
511.60
349.01
% Of Sales
-
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
11.68%
9.76%
General & Admin Exp.
-
1,006.68
1,068.22
997.32
686.38
666.38
283.49
197.83
130.74
120.34
116.94
% Of Sales
-
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
2.75%
3.27%
Selling & Distn. Exp.
-
1,122.67
1,025.85
848.43
901.87
878.98
359.60
305.98
208.20
141.59
143.56
% Of Sales
-
5.74%
6.23%
5.69%
6.54%
7.25%
4.44%
5.23%
4.50%
3.23%
4.02%
Miscellaneous Exp.
-
416.33
298.75
203.97
187.92
227.09
123.20
149.49
111.96
47.53
143.56
% Of Sales
-
2.13%
1.81%
1.37%
1.36%
1.87%
1.52%
2.55%
2.42%
1.08%
1.37%
EBITDA
4,430.47
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
963.26
823.19
EBITDA Margin
20.50%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
21.98%
23.02%
Other Income
132.52
155.32
101.98
115.89
203.80
96.71
21.56
28.54
24.70
71.41
151.49
Interest
188.56
262.60
77.72
66.72
256.70
159.87
310.16
266.64
277.24
64.65
73.09
Depreciation
833.91
667.95
557.97
427.63
392.37
332.61
312.53
248.74
200.53
171.50
149.34
PBT
3,453.84
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
798.52
752.25
Tax
888.03
726.85
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
225.12
191.36
Tax Rate
25.71%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
28.56%
25.44%
PAT
2,565.81
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
563.45
561.21
PAT before Minority Interest
2,566.46
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
563.06
560.89
Minority Interest
0.65
0.23
0.26
0.47
1.50
4.51
3.78
2.46
0.64
0.39
0.32
PAT Margin
11.87%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
12.86%
15.70%
PAT Growth
17.20%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
337.94%
-121.92%
0.40%
 
Unadjusted EPS
43.92
40.36
41.36
39.33
34.67
27.03
40.27
10.09
-4.24
19.57
20.81

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
2,444.83
1,829.08
Share Capital
58.59
58.59
58.59
58.52
29.20
29.15
29.12
29.11
29.11
27.86
Total Reserves
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
2,415.72
1,801.22
Non-Current Liabilities
335.81
594.11
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
645.49
2,245.74
Secured Loans
179.95
451.20
177.59
380.10
773.54
1,101.31
1,084.11
862.08
449.74
864.05
Unsecured Loans
0.00
0.00
3.81
362.71
587.93
178.05
64.15
102.55
73.61
1,290.51
Long Term Provisions
46.54
55.86
39.13
23.36
24.35
9.18
9.00
4.24
3.09
0.00
Current Liabilities
12,042.90
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
2,768.49
707.99
Trade Payables
2,677.13
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
776.35
604.40
Other Current Liabilities
2,545.41
1,967.42
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
699.09
68.40
Short Term Borrowings
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
1,234.73
0.00
Short Term Provisions
247.15
294.23
261.36
132.93
218.24
126.60
80.09
66.36
58.32
35.19
Total Liabilities
26,271.08
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14
Net Block
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
1,738.60
1,710.85
Gross Block
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
2,438.00
2,407.67
Accumulated Depreciation
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
699.40
696.82
Non Current Assets
10,906.57
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
2,546.75
2,280.47
Capital Work in Progress
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
582.86
570.08
Non Current Investment
360.20
311.52
245.85
122.94
0.14
19.76
22.24
19.86
38.49
-0.46
Long Term Loans & Adv.
364.44
261.91
256.48
236.56
455.27
789.04
237.82
108.12
110.77
0.00
Other Non Current Assets
38.62
86.93
81.29
32.24
30.25
18.40
18.66
0.12
1.47
0.00
Current Assets
15,364.51
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
3,321.18
2,506.67
Current Investments
0.02
0.02
0.02
0.02
19.65
0.03
0.04
18.68
0.04
0.74
Inventories
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
1,455.27
1,102.45
Sundry Debtors
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
1,230.98
956.01
Cash & Bank
1,957.18
1,262.25
513.48
800.26
469.11
178.58
208.45
70.86
186.72
72.83
Other Current Assets
2,747.93
1,223.32
1,084.72
464.37
659.57
448.46
407.69
388.98
448.17
374.64
Short Term Loans & Adv.
828.11
753.96
512.09
366.88
387.90
237.22
207.51
216.67
358.87
280.60
Net Current Assets
3,321.61
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
552.69
1,798.68
Total Assets
26,271.08
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,622.03
1,954.52
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
335.11
425.18
PBT
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
798.52
752.25
Adjustment
810.77
535.02
408.92
487.50
406.28
515.12
441.54
387.22
197.72
99.77
Changes in Working Capital
-1,510.26
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
-469.45
-273.72
Cash after chg. in Working capital
2,391.86
2,653.08
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
526.79
578.30
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
-191.68
-153.12
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,876.83
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
-599.07
-399.02
Net Fixed Assets
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
-396.28
-478.66
Net Investments
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
-122.17
-101.50
Others
-1,706.27
-870.04
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
-80.62
181.14
Cash from Financing Activity
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
406.98
-84.04
Net Cash Inflow / Outflow
664.26
892.08
-423.72
339.99
-67.95
-54.82
136.62
-118.06
143.02
-57.88
Opening Cash & Equivalents
1,209.94
318.03
743.49
403.81
148.02
202.73
65.64
183.71
44.72
102.65
Closing Cash & Equivalent
1,875.58
1,209.94
319.63
743.50
461.10
148.02
202.73
65.64
183.71
47.19

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
237.08
199.36
159.96
124.50
88.29
64.33
44.74
40.19
41.99
32.83
ROA
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
10.57%
12.45%
ROE
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
26.35%
36.54%
ROCE
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
19.29%
21.84%
Fixed Asset Turnover
2.13
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
1.67
Receivable days
60.58
64.66
89.16
106.53
91.84
93.55
86.28
95.44
89.07
92.25
Inventory Days
122.24
112.70
101.43
100.27
88.91
94.82
105.51
115.91
104.17
98.97
Payable days
60.06
67.77
75.73
81.50
67.49
71.06
57.79
64.70
70.79
72.18
Cash Conversion Cycle
122.76
109.58
114.86
125.30
113.25
117.31
134.00
146.65
122.45
119.04
Total Debt/Equity
0.50
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
1.18
Interest Cover
12.76
42.66
46.80
11.69
14.56
5.94
2.40
0.23
13.19
11.29

News Update


  • USFDA completes inspection at Aurobindo Pharma’s Unit IV
    14th Nov 2019, 11:33 AM

    At the end of the inspection, the company has been issued a Form 483 with 14 observations

    Read More
  • Aurobindo Pharma reports 5% rise in Q2 consolidated net profit
    13th Nov 2019, 10:39 AM

    Total consolidated income of the company increased by 17.65% at Rs 5,621.09 crore for Q2FY20

    Read More
  • Aurobindo Pharma - Quarterly Results
    12th Nov 2019, 18:04 PM

    Read More
  • Aurobindo Pharma gets 8 observations from USFDA for two units in Hyderabad
    6th Nov 2019, 15:26 PM

    The USFDA inspected two units between October 21, 2019 and October 28, 2019

    Read More
  • Aurobindo Pharma gets USFDA’s nod for Guaifenesin Extended-Release Tablets
    24th Oct 2019, 11:18 AM

    The company’s Guaifenesin extended-release tablets are the AB rated generic equivalent of RB Health LLC’s Mucinex tablets

    Read More
  • Aurobindo Pharma gets 7 observations from USFDA for Telangana Unit
    9th Oct 2019, 09:20 AM

    The company is confident of addressing these issues within the stipulated timeline

    Read More
  • SEBI slaps penalty of Rs 22 crore on Aurobindo Pharma for insider trading
    24th Sep 2019, 10:19 AM

    The probe found that the promoter entities traded in the scrip of the company based on unpublished price sensitive information

    Read More
  • Aurobindo Pharma’s arm signs deal to set up JV in China
    31st Aug 2019, 15:33 PM

    Helix Healthcare S.V, Netherlands, has entered into an agreement with Shanghai LongJin Investment Company, China and Sveva Capitals, Hongkong

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.